Veterinary api Ingredients, animal nutrition raw materials and feed additives manufacturer and supplier

Industry Dynamics

TFF Pharma: The Potential Is Still Very Much Present

  • While the company added three more big pharma partners, this is not what shareholders prefer to hear as the company already has more than two dozen of these.

  • These partnerships are mostly in the pre-clinical phase and are unlikely to lead to near-time monetization.

  • For monetization, there are four near-time candidates, Voriconozale and Tacrolimus look to be the most certain candidates but PLUS (cannabis) and UNION (Niclosamide) are additional deal candidates.

  • A deal is necessary as cash levels are getting low, which might necessitate earlier partnering and forfeiting some future revenue.

  • But just one deal with upfront payments is likely to considerably improve their situation so the stock remains very interesting.

  • Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. 

Latest News

Contact Us



Email:[email protected]

ADD: Room C405, No. 488,Cuishan Rd, Xishan District, Wuxi City Jiangsu Province, China